Regeneron Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Regeneron Pharmaceuticals Inc cash flow-to-debt ratio. Regeneron Pharmaceuticals Inc (REGN) has a Cash Flow-to-Debt Ratio of 0.06x as of June 2026, meaning its operating cash flow of $574.50 Million could theoretically repay 0% of its total liabilities ($10.02 Billion) in one year. Check REGN cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Regeneron Pharmaceuticals Inc (1991–2025)
Cash flow-to-debt ratio of Regeneron Pharmaceuticals Inc from 1991 to 2025. Historical debt coverage capacity for Regeneron Pharmaceuticals Inc across 35 annual periods. Check REGN cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Regeneron Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (1991–2025)
Regeneron Pharmaceuticals Inc cash flow-to-debt ratio by year from 1991 to 2025. Year-by-year debt coverage analysis for Regeneron Pharmaceuticals Inc. For the full cash flow conversion analysis, see cash efficiency ratio of Regeneron Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.54x | $4.98 Billion | $9.30 Billion | ▲ +1.8% |
| 2024 | 0.53x | $4.42 Billion | $8.41 Billion | ▼ -18.6% |
| 2023 | 0.65x | $4.59 Billion | $7.11 Billion | ▼ -15.6% |
| 2022 | 0.77x | $5.01 Billion | $6.55 Billion | ▼ -27.9% |
| 2021 | 1.06x | $7.08 Billion | $6.67 Billion | ▲ +149.1% |
| 2020 | 0.43x | $2.62 Billion | $6.14 Billion | ▼ -34.8% |
| 2019 | 0.65x | $2.43 Billion | $3.72 Billion | ▼ -11.3% |
| 2018 | 0.74x | $2.20 Billion | $2.98 Billion | ▲ +47.8% |
| 2017 | 0.50x | $1.31 Billion | $2.62 Billion | ▼ -15.3% |
| 2016 | 0.59x | $1.49 Billion | $2.52 Billion | ▼ -13.6% |
| 2015 | 0.68x | $1.33 Billion | $1.95 Billion | ▲ +20.3% |
| 2014 | 0.57x | $752.43 Million | $1.33 Billion | ▼ -3.9% |
| 2013 | 0.59x | $588.60 Million | $998.94 Million | ▲ +759.5% |
| 2012 | -0.09x | $-74.61 Million | $835.11 Million | ▲ +47.2% |
| 2011 | -0.17x | $-141.68 Million | $837.85 Million | ▼ -198.6% |
| 2010 | 0.17x | $96.34 Million | $561.62 Million | ▲ +181.8% |
| 2009 | -0.21x | $-72.23 Million | $344.44 Million | ▲ +40.9% |
| 2008 | -0.35x | $-89.09 Million | $251.19 Million | ▼ -716.7% |
| 2007 | 0.06x | $27.37 Million | $475.99 Million | ▼ -8.2% |
| 2006 | 0.06x | $23.07 Million | $368.47 Million | ▲ +164.0% |
| 2005 | -0.10x | $-30.30 Million | $309.50 Million | ▼ -68.2% |
| 2004 | -0.06x | $-16.91 Million | $290.56 Million | ▼ -224.4% |
| 2003 | -0.02x | $-6.13 Million | $341.91 Million | ▲ +96.0% |
| 2002 | -0.45x | $-110.52 Million | $245.59 Million | ▼ -79.8% |
| 2001 | -0.25x | $-57.32 Million | $229.04 Million | ▲ +76.6% |
| 2000 | -1.07x | $-27.91 Million | $26.14 Million | ▼ -112.7% |
| 1999 | -0.50x | $-13.80 Million | $27.50 Million | ▼ -26.4% |
| 1998 | -0.40x | $-10.20 Million | $25.70 Million | ▼ -91.9% |
| 1997 | -0.21x | $-6.10 Million | $29.50 Million | ▲ +68.7% |
| 1996 | -0.66x | $-20.30 Million | $30.70 Million | ▲ +5.9% |
| 1995 | -0.70x | $-18.20 Million | $25.90 Million | ▲ +7.1% |
| 1994 | -0.76x | $-20.50 Million | $27.10 Million | ▲ +51.7% |
| 1993 | -1.57x | $-30.10 Million | $19.20 Million | ▲ +2.5% |
| 1992 | -1.61x | $-17.20 Million | $10.70 Million | ▼ -84.4% |
| 1991 | -0.87x | $-6.80 Million | $7.80 Million | — |